Delayed Liver Function Impairment Secondary to Interferon β-1a Use in Multiple Sclerosis

Area of Science:

• Neurology
• Hepatology
• Immunology

Background:

• Interferon beta-1a is a standard immunomodulatory therapy for multiple sclerosis (MS).
• Liver function impairment is a known, typically early, side effect of interferon therapy.
• Standard monitoring usually focuses on the initial 6 months of treatment.

Observation:

• Two multiple sclerosis patients developed liver function impairment 5 years after initiating interferon beta-1a treatment.
• Hepatological evaluations ruled out other causes for the liver dysfunction.
• Discontinuation of interferon beta-1a led to the recovery of liver function in both cases.

Findings:

• Interferon beta-1a can induce delayed liver function impairment, manifesting up to 5 years after treatment initiation.
• This delayed reaction appears to be an idiosyncratic response to interferon beta-1a.
• Early identification and cessation of the drug are key to managing this adverse effect.

Implications:

• Extended liver function monitoring is recommended for multiple sclerosis patients on interferon beta therapy, beyond the initial 6 months.
• Clinicians should consider interferon beta-1a as a potential cause of delayed liver injury, even years into treatment.
• Caution is advised for patients using interferon beta-1a concurrently with other potentially hepatotoxic medications.